Skip to main content

Advertisement

SpringerLink
Log in

A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

A higher extent of resection (EOR) in WHO grade II gliomas (GIIG) is correlated with longer survival. However, the molecular markers also feature prognostic relevance. Here, we examined whether maximal EOR was related to the genetic profile. We retrospectively investigated the predictive value of 1p19q, IDH1, 53 expression and Ki67 index for the EOR in 200 consecutive GIIGs (2007–2013). Data were modeled in a linear model. The analysis was performed with two statistical methods (arcsin-sqrt and Beta-regression model with logit link). There was no deletion 1p19q in 118 cases, codeletion 1p19q (57 cases), single deletion 1p (4 cases) or19q (16 cases). 155 patients had a mutation of IDH1. p53 was graded in 4 degrees (0:92 cases, 1:52 cases, 2:31 cases, 3:8 cases). Mean Ki67 index was 5.2 % (range 1–20 %). Mean preoperative tumor volume was 60.8 cm3 (range 3.3–250 cm3) and mean EOR was 0.917 (range 0.574–1). The statistical analysis was significant for a lower EOR in patients with codeletion 1p19q (OR 0.738, p = 0.0463) and with a single deletion 19q (OR 0.641, p = 0.0168). There was no significant correlation between IDH1 or p53 and the EOR. Higher Ki67 was marginally associated with higher EOR (p = 0.0603). The study demonstrates in a large cohort of GIIG that a higher EOR is not attributable to favorable genetic markers. This original result supports maximal surgical resection as an important therapeutic factor per se to optimize prognosis, independently of the molecular pattern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van den Bent MJ, Snijders TJ, Bromberg JE (2012) Current treatment of low grade gliomas. Memo 5:223–227

    Article  PubMed Central  PubMed  Google Scholar 

  2. Bryszewski B, Tybor K, Ormezowska EA, Jaskolski DJ, Majos A (2013) Rearrangement of motor centers and its relationship to the neurological status of low-grade glioma examined on pre- and postoperative fMRI. Clin Neurol Neurosurg 115:2464–2470

    Article  PubMed  Google Scholar 

  3. Takahashi S, Jussen D, Vajkoczy P, Picht T (2012) Plastic relocation of motor cortex in a patient with LGG (low grade glioma) confirmed by NBS (navigated brain stimulation). Acta Neurochir (Wien) 154:2003–2008

    Article  Google Scholar 

  4. Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, Boulay JL, Mariani L (2013) IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol 15:469–479

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG (2011) Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 81:218–224

    Article  PubMed Central  PubMed  Google Scholar 

  6. Zhao J, Ma W, Zhao H (2014) Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol 16:103–112

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kim W, Liau LM (2012) IDH mutations in human glioma. Neurosurg Clin N Am 23:471–480

    Article  PubMed Central  PubMed  Google Scholar 

  8. Cohen AL, Holmen SL, Colman H (2013) IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13:345

    Article  PubMed Central  PubMed  Google Scholar 

  9. Lewandowska MA, Furtak J, Szylberg T, Roszkowski K, Windorbska W, Rytlewska J, Jóźwicki W (2014) An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) Mutation in polish glioma patients. Mol Diagn Ther 18:45–53

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708–2714

    Article  PubMed Central  PubMed  Google Scholar 

  11. Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12:143–147

    Article  PubMed  Google Scholar 

  12. Torp SH (2002) Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol 21:252–257

    CAS  PubMed  Google Scholar 

  13. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Li SW, Song YJ, Kang CS, Jiang T (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol 14:230–241

    Article  PubMed Central  PubMed  Google Scholar 

  14. Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H (2013) Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg 118:1157–1168

    Article  PubMed  Google Scholar 

  15. Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Párraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137:449–462

    Article  PubMed  Google Scholar 

  16. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, Solheim O (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308:1881–1888

    Article  CAS  PubMed  Google Scholar 

  17. Ius T, Pauletto G, Isola M, Gregoraci G, Budai R, Lettieri C, Eleopra R, Fadiga L, Skrap M (2014) Surgery for insular low-grade glioma: predictors of postoperative seizure outcome. J Neurosurg 120:12–23

    Article  PubMed  Google Scholar 

  18. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338–13345

    Article  PubMed  Google Scholar 

  19. Yordanova YN, Moritz-Gasser S, Duffau H (2011) Awake surgery for WHO Grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection. J Neurosurg 115:232–239

    Article  PubMed  Google Scholar 

  20. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–1133

    Article  CAS  PubMed  Google Scholar 

  21. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30:2559–2565

    Article  PubMed  Google Scholar 

  22. Duffau H, Lopes M, Arthuis F, Bitar A, Sichez JP, Van Effenterre R, Capelle L (2005) Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985–1996) and with (1996–2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76:845–851

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed Central  PubMed  Google Scholar 

  24. Goze C, Mansour L, Rigau V, Duffau H (2013) Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas. J Neurosurg 118:866–872

    Article  CAS  PubMed  Google Scholar 

  25. Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA (1995) Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 73:837–843

    CAS  PubMed  Google Scholar 

  26. Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M (1993) p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer 55:982–987

    Article  CAS  PubMed  Google Scholar 

  27. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31–38

    Article  CAS  PubMed  Google Scholar 

  28. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117–1124

    CAS  PubMed  Google Scholar 

  29. Cribari-Neto F, Zileis A (2010) Beta Regression in R. J Stat Soft 34:1–24

    Google Scholar 

  30. Duffau H (2012) The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir (Wien) 154:569–574

    Article  Google Scholar 

  31. Duffau H, Gatignol P, Mandonnet E, Capelle L, Taillandier L (2008) Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J Neurosurg 109:461–471

    Article  PubMed  Google Scholar 

  32. Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G (2009) Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 53:305–309

    Article  CAS  PubMed  Google Scholar 

  33. Goze C, Bezzina C, Goze E, Rigau V, Maudelonde T, Bauchet L, Duffau H (2012) 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol 108:69–75

    Article  PubMed  Google Scholar 

  34. Goze C, Rigau V, Gibert L, Maudelonde T, Duffau H (2009) Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol 91:1–5

    Article  CAS  PubMed  Google Scholar 

  35. Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, Crinière E, Capelle L, Duffau H, Cornu P, Broët P, Kujas M, Mokhtari K, Carpentier A, Sanson M, Hoang-Xuan K, Thillet J, Delattre JY (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360–2362

    Article  CAS  PubMed  Google Scholar 

  36. Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306

    Article  PubMed  Google Scholar 

  37. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891

    Article  PubMed  Google Scholar 

  38. Spena G, D’Agata F, Panciani PP, Buglione di Monale M, Fontanella MM (2013) Supratentorial gliomas in eloquent areas: which parameters can predict functional outcome and extent of resection? PLoS One 8:e80916

    Article  PubMed Central  PubMed  Google Scholar 

  39. Labussière M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Criniere E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74:1886–1890

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Research Fund of the University of Basel and the Voluntary Academic Society of Basel.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Av Augustin Fliche, 34295, Montpellier, France

    Dominik Cordier & Hugues Duffau

  2. Department of Neurosurgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland

    Dominik Cordier & Luigi Mariani

  3. Tumoral cellular and tissular Biopathology Department, Cell Biology Laboratory, Arnaud de Villeneuve Hospital, Montpellier University Medical Center, Montpellier, France

    Catherine Gozé

  4. National Institute for Health and Medical Research (INSERM), U1051 Laboratory, Team “Brain Plasticity, Stem Cells and Glial Tumors”, Institute for Neurosciences of Montpellier, Montpellier University Medical Center, 34091, Montpellier, France

    Catherine Gozé, Valérie Rigau & Hugues Duffau

  5. Clinical Trial Unit, University Hospital Basel, Schanzenstrasse 55, 4031, Basel, Switzerland

    Sabine Schädelin

  6. Tumoral cellular and tissular Biopathology Department, Cytology and Anatomical Pathology Laboratory, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Av Augustin Fliche, 34295, Montpellier, France

    Valérie Rigau

Authors
  1. Dominik Cordier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Gozé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine Schädelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valérie Rigau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luigi Mariani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hugues Duffau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hugues Duffau.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cordier, D., Gozé, C., Schädelin, S. et al. A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers. J Neurooncol 121, 185–193 (2015). https://doi.org/10.1007/s11060-014-1623-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1623-y

Keywords

Search

Navigation